Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.71 per share which missed the analyst consensus estimate of $6.18 by 7.61 percent. This is a 169.21 percent increase over losses of $(8.25) per share from the same period last year. The company reported quarterly sales of $1.208 billion which beat the analyst consensus estimate of $1.115 billion by 8.29 percent. This is a 15.49 percent increase over sales of $1.046 billion the same period last year.